Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
NAD Challenges InflameAway Celadrin Claims
May 19, 2010
3 Min Read
NEW YORKThe National Advertising Division (NAD) of the Council of Better Business Bureaus has recommended Imagenetix discontinue certain advertising claims on product labeling and in television advertising for the dietary supplement InflameAway Celadrin. The claims at issue were challenged by Schiff Nutrition Group Inc.
Claims at issue included:
Clinically tested and shown to be effective for improving joint comfort
Celadrin Softgels: Clinically Tested and Proven to Work
Celadrin is demonstrated to be faster and more effective than glucosamine/chondroitin
Now theres something proven to be better! InflameAway Celadrin®
Because InflameAway Celadrin® works 6 times faster, 6 times more effective
If youre taking glucosamine/chondroitin, then you need to know that theres a better product that can dramatically restore your joint health
InflameAway Celadrin works not just twice as fast, or four times as fast, all-natural InflameAway works 6 times faster than glucosamine/chondroitin
Clinically proven 6 times faster
Six times faster, and six times more effective too
Demonstrated to be 6x faster and 6x more effective than glucosamine/chondroitin
Available for oral and topical applicants, Celadrins beneficial effects have been proven to work 6 times faster than glucosamine or chondroitin.
In a double blind clinical trial, oral Celadrin showed significant benefit beyond arthritic medication the subjects had been taking with cumulative improvement shown throughout the study
Celadrins beneficial effects have been proven superior in results to glucosamine, chondroitin, MSM and SAMe and other arthritic medications
Patented InflameAway Celadrin is a medical breakthrough
Imagenetix informed NAD the company had been revising its marketing campaign prior to the NAD challenge and had discontinued all of its comparative claims versus glucosamine/chondroitin (and other joint-health products), as well as its claim that Celadrin has been Proven to work. NAD found the advertisers permanent discontinuance of all of its comparative claims versus glucosamine/chondroitin to be necessary and proper.
The advertiser relied on studies conducted on various formulations of Celadrin to support the claim Clinically tested and shown to be effective for improving joint comfort. NAD was concerned by the changes in formulation of Celadrin, both from study to study, and from the studies to the currently marketed formula of Celadrin.
NAD found the evidence in the record was inconsistent and insufficient to support a claim that either Celadrin, or its active ingredient, cetylated fatty acid, has been Clinically tested and shown to be effective for improving joint comfort. Further, NAD noted, while the patent on the ingredient is evidence of its novelty, the patent alone cannot support a clinically shown claim.
Finally, NAD found that the claim that Patented InflameAway Celadrin is a medical breakthrough, was not supported by the research on Celadrin or by the patent on the key ingredient in Celadrin and recommended that it be discontinued.
The company, in its advertisers statement, said it is extremely disappointed the unrebutted opinions of two highly qualified scientific experts have been rejected in favor of the non-scientific judgment made by NAD counsel. However, the company said it has and will continue to voluntarily discontinue the use of all NAD challenged claims in its national advertising.
You May Also Like
